Achieving Optimal Outcomes in Chronic Lymphocytic Leukaemia
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 61 (5) , 593-611
- https://doi.org/10.2165/00003495-200161050-00005
Abstract
No abstract availableKeywords
This publication has 131 references indexed in Scilit:
- Ochroconis gallopava endophthalmitis in fludarabine treated chronic lymphocytic leukaemiaBritish Journal of Ophthalmology, 2000
- Myelodysplastic following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)Leukemia, 1997
- Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patientsBritish Journal of Haematology, 1996
- Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Acute Onset of Severe Autoimmune Hemolytic Anemia After Treatment With 2‐Chlorodeoxyadenosine for Chronic Lymphocytic LeukemiaAmerican Journal of Hematology, 1995
- Effect of lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemiaCancer, 1994
- Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatmentAnnals of Hematology, 1992
- Pentostatin in Refractory Chronic Lymphocytic Leukemia: A Phase II Trial of the European Organization for Research and Treatment of CancerJNCI Journal of the National Cancer Institute, 1990
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1988
- A clinical staging system for chronic lymphocytic leukemia.Prognostic significanceCancer, 1977